Mr. Andrew Dodson
- Director, UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH). Member of the Board of Assessors since 1995: became Deputy Director for the Scheme in 2007.
- Executive Board representative for ICC & ISH and Divisional Representative for Cellular Pathology Division.
- Worked within the NHS since 1981, qualifying as a Biomedical Scientist in Histopathology while working at St. George's Hospital in London in 1984
- Moved to Liverpool in 1990 and ran the Immunocytochemistry service and latterly the Molecular Pathology service at the Royal Liverpool University Hospital until 2013
- Returned to London to take up a role as a Senior Research Clinical Scientist in the Breast Cancer Research Unit at the Royal Marsden Hospital
- Took post as Deputy Director UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH) in 2007. At the end of 2018, was appointed as its Director.
OTHER PROFESSIONAL ROLES INCLUDE
- Postgraduate course author and tutor for University of Greenwich ICC and diagnostic breast cancer courses
- Chair of Institute of Biomedical Science (IBMS) ICC Diploma of Expert Practice Working Group
- Member of IBMS Scientific Advisory Panel for Cellular Pathology